Sudhir Agrawal

Sudhir Agrawal is a Professor at UMass Chan Medical School, Department of Medicine, affiliated with the T.H. Chan School of Medicine. He specializes in RNA therapeutics, focusing on antisense technology, Toll-Like Receptor (TLR) agonism/antagonism, and drug discovery. His work has led to three drug-discovery platforms, with several clinical trials and approved therapies derived from his research. Agrawal holds a DPhil from the University of Cambridge and completed postdoctoral training at the University of Massachusetts Medical School.

His research interests include developing nucleic acid-based therapies, understanding TLR signaling pathways, and their applications in oncology, infectious diseases, and autoimmune conditions. Key contributions include the design of TLR9 agonists for cancer immunotherapy and antisense oligonucleotides targeting XIAP for cancer treatment.

Publications highlight his work on TLR modulation, RNA chemistry, and translational medicine. Notable achievements include the 2022 Lifetime Achievement Award from the Oligonucleotide Therapeutic Society, recognizing his pioneering role in RNA therapeutics. Collaborations with institutions like the MRC Laboratory of Molecular Biology and co-authors such as E.R. Kandimalla underscore his impactful research network.

His work spans preclinical and clinical stages, emphasizing immune modulation and drug development. Future directions include advancing TLR-based therapies and exploring allele-specific antisense oligonucleotides for genetic disorders.